We emulated the design of a hypothetical pragmatic randomised controlled trial by comparing three antidiabetic drug classes (sulfonylureas, DPP-4 inhibitors, and SGLT-2 inhibitors) of interest to the broad population of people with type 2 diabetes mellitus who, according to current NICE guidelines, are eligible for any of these second line treatments. This evidence concerns the gene SLC5A2 and diabetes mellitus.